Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 6/20 | 0.48 |
| ▸ | METAP2 | P50579 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | S100A9 | P06702 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13852970 | 0.89 | ALDH1A1 (0.60) | NPC1RAB9AMETAP2ALDH1A1MAPT | |
| SCHEMBL13852963 | 0.88 | PKM (0.54) | NPC1RAB9AMETAP2ALDH1A1MAPT | |
| SCHEMBL13852947 | 0.82 | NPC1 (0.58) | NPC1RAB9AMETAP2ALDH1A1MAPT | |
| SCHEMBL3988400 | 0.81 | METAP2 (0.74) | ACLYMETAP2 | |
| SCHEMBL13629407 | 0.80 | NHERF1 (0.62) | ALDH1A1MAPT | |
| SCHEMBL13853043 | 0.80 | MCL1 (0.50) | TP53 | |
| SCHEMBL13629412 | 0.79 | ALDH1A1 (0.48) | NPC1RAB9AMETAP2ALDH1A1MAPT | |
| SCHEMBL13615239 | 0.78 | HSD17B2 (0.52) | ACLYALDH1A1 | |
| SCHEMBL13852965 | 0.78 | BRD4 (0.52) | METAP2ALDH1A1 | |
| SCHEMBL13629459 | 0.78 | FFAR4 (0.71) | NPC1RAB9AALDH1A1FFAR4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | NPC1 4249/4885RAB9A 2467/4885ACLY 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.